Market Overview

ELIQUIS Receives Approval In Japan for Prevention of Stroke, Systemic Embolism In Patients with Nonvalvular Atrial Fibrillation

Related BMY
Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
The Stocks Already in Correction Mode (Fox Business)

Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced
today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has
approved ELIQUIS® (apixaban) for the prevention of
ischemic stroke and systemic embolism in patients with nonvalvular
atrial fibrillation (NVAF). ELIQUIS is a novel anticoagulant that has
demonstrated risk reductions versus warfarin in three important outcomes
of stroke, major bleeding and all-cause death. ELIQUIS is an oral direct
Factor Xa inhibitor, part of a novel therapeutic class. This is the
third approval for ELIQUIS for the prevention of stroke and systemic
embolism in patients with nonvalvular atrial fibrillation, following
approvals in the European Union and Canada.

“Today's approval of ELIQUIS is

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (BMY + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters